Regulatory Changes in Pharmaceutical Pricing Spark Debate

In a recent statement, the President of the German Federal Association of Pharmacists (ABDA), Thomas Preis, expressed strong opposition to the inclusion of discounts and bonuses in the pharmaceutical and healthcare sectors. He emphasized that medicines should not be treated as mere commercial goods due to their complex risk profiles, highlighting the necessity for regulations that prioritize patient safety and care.

This statement follows a ruling by the Federal Court of Justice (BGH), which confirmed an earlier decision by the European Court of Justice (ECJ) regarding price regulation for prescription drugs. The ECJ had previously lifted the price regulation for prescription medications sold by online pharmacies, a decision that sent shockwaves through the pharmacy community.

To maintain price regulation, German lawmakers relocated the relevant provisions from the Medicines Act to the Social Code V in 2020 through the Local Pharmacy Strengthening Act. This legislative shift means that the price regulation is now viewed as part of the statutory health insurance framework, ensuring a uniform price for prescription drugs for patients covered by statutory health insurance, regardless of whether they are purchased from local pharmacies or EU-based online pharmacies. Notably, discounts or bonuses for prescription medications are prohibited for statutory health insurance beneficiaries.

Preis urged policymakers to quickly devise solutions if there are doubts about the validity of the current prescription price regulation. He expressed confidence that the social law-based price regulation established by the Local Pharmacy Strengthening Act would remain intact, pending the review of the court's written reasoning.

The BGH's recent ruling dismissed a case brought by the Bavarian Pharmacists' Association against a now-defunct subsidiary of the online pharmacy Doc Morris. Preis lamented the outcome, acknowledging the setback for the Bavarian Pharmacists' Association. In contrast, online pharmacies responded positively, with Doc Morris announcing plans to reintroduce bonuses immediately. Additionally, Redcare viewed the ruling as a reinforcement of patient rights.

As the debate continues, the implications of these regulatory changes on the pharmaceutical market and patient access to medications remain to be seen. Stakeholders from various sectors are expected to monitor the developments closely, advocating for policies that balance business interests with the imperative of patient safety and affordability.